Boomerang Medical Secures $20M for Groundbreaking Ulcerative Colitis Therapy
September 10, 2025, 9:36 pm
Boomerang Medical, a women-led pioneer in bioelectronic medicine, has secured $20 million in Series B funding. This critical investment fuels BOOM-IBD2, its pivotal clinical trial. The trial targets Ulcerative Colitis, a severe and widespread autoimmune disease. Millions worldwide suffer its chronic symptoms. Current device-based therapies for IBD are scarce. Boomerang Medical is developing implantable neuromodulation. This innovative approach uses gentle electrical stimulation. It aims to reduce symptom burden. It seeks to vastly improve patient quality of life. The company, headquartered in Mountain View, California, is advancing a new frontier. They build on sacral neuromodulation’s established safety record. The funding accelerates patient enrollment across the U.S. This marks a significant stride in addressing urgent unmet needs. It promises to transform treatment paradigms for chronic gastrointestinal conditions. This breakthrough could redefine care.
Boomerang Medical announced a major financial milestone. The company secured $20 million in Series B funding. This substantial investment will drive critical research. It focuses on inflammatory bowel disease (IBD) treatment. Arboretum Ventures and Hatteras Venture Partners co-led the round. This capital infusion signifies strong investor confidence. It empowers Boomerang Medical’s innovative mission.
The funding's primary goal is to advance BOOM-IBD2. This is a pivotal clinical trial. It evaluates implantable neuromodulation for IBD. The initial focus is Ulcerative Colitis. This chronic autoimmune disorder affects millions. Its unpredictable nature is devastating. Patients endure severe symptoms. These include chronic pain, debilitating diarrhea, and profound fatigue. Ulcerative Colitis profoundly impacts daily life. It significantly reduces quality of life. Current pharmacological treatments often fall short for many. Invasive surgeries are sometimes the only remaining option. Device-based solutions for IBD are virtually non-existent. This represents a significant unmet medical need.
Boomerang Medical seeks to fill this critical gap. The company champions bioelectronic medicine. This cutting-edge field merges biology and electronics. It develops innovative devices. These devices modulate specific nerve activity. Their approach involves sacral neuromodulation. A small, discreet implanted device delivers gentle electrical stimulation. This therapy modulates neural pathways. It aims to restore normal gut function. It works to alleviate symptoms. It strives to improve patient well-being significantly. Sacral neuromodulation boasts a robust safety profile. Over 500,000 procedures have occurred globally. These procedures successfully address other medical conditions. This extensive, proven track record underpins the therapy's safety. It provides a strong foundation for its application in IBD.
BOOM-IBD2 represents a groundbreaking effort. It is the first pivotal trial of implantable neuromodulation. The trial specifically targets IBD. Patient enrollment is actively underway. Leading medical centers across the United States participate. The clinical trial identifier is NCT06571669. This public registry ensures transparency. It highlights the rigorous scientific approach.
The trial design is not arbitrary. It draws from prior research. Boomerang Medical completed a 40-patient feasibility study. This study included both Crohn's disease and Ulcerative Colitis patients. The findings provided crucial insights. They informed BOOM-IBD2’s comprehensive design. Safety, tolerability, and early efficacy signals emerged. These early successes paved the way. They justify the larger pivotal investigation.
Boomerang Medical operates from a unique vantage point. It is headquartered in Mountain View, California. The company resides on the campus of El Camino Hospital. It holds a Company-In-Residence status. This affiliation is with Fogarty Innovation. Fogarty Innovation is a premier healthcare-focused incubator. It is the only one of its kind in the U.S. This environment fosters rapid medical device development. It cultivates groundbreaking solutions.
Leadership also defines Boomerang Medical. Heather Simonsen leads as CEO. The company is notably women-led. This highlights diversity in medical innovation. Their commitment to underserved populations is clear. Rigorous science guides their every step. Thoughtful innovation is their hallmark.
The potential impact is immense. Ulcerative Colitis is the most prevalent IBD form. Its widespread global impact demands urgent new solutions. Millions of lives hang in the balance. If successful, BOOM-IBD2 could introduce a completely new class of therapies. These pioneering device-based treatments would revolutionize care. They would target complex autoimmune gastrointestinal conditions. Such a breakthrough would redefine patient care. It would offer unprecedented new hope for millions of sufferers. This innovation signifies a paradigm shift in IBD management.
The Crohn’s & Colitis Foundation recognized Boomerang Medical. They named it an "Emerging Leader in IBD." This prestigious acknowledgment validates their work. It underscores their dedication to patient advocacy. It affirms their innovative trajectory.
Investors like Arboretum Ventures see clear value. Hatteras Venture Partners share this vision. They recognize the significant unmet need. They see the potential for a transformative solution. This $20 million investment positions Boomerang Medical strongly. It enables them to complete the pivotal trial. It moves this promising therapy closer to patients.
Boomerang Medical’s vision extends beyond Ulcerative Colitis. They aim to bring precision neuromodulation. It targets various underserved patient populations. This latest funding empowers this broader goal. It accelerates their clinical pipeline. The company stands ready to reshape the treatment landscape. This commitment drives progress in bioelectronic medicine. It promises a future with better outcomes for chronic conditions.
Boomerang Medical announced a major financial milestone. The company secured $20 million in Series B funding. This substantial investment will drive critical research. It focuses on inflammatory bowel disease (IBD) treatment. Arboretum Ventures and Hatteras Venture Partners co-led the round. This capital infusion signifies strong investor confidence. It empowers Boomerang Medical’s innovative mission.
The funding's primary goal is to advance BOOM-IBD2. This is a pivotal clinical trial. It evaluates implantable neuromodulation for IBD. The initial focus is Ulcerative Colitis. This chronic autoimmune disorder affects millions. Its unpredictable nature is devastating. Patients endure severe symptoms. These include chronic pain, debilitating diarrhea, and profound fatigue. Ulcerative Colitis profoundly impacts daily life. It significantly reduces quality of life. Current pharmacological treatments often fall short for many. Invasive surgeries are sometimes the only remaining option. Device-based solutions for IBD are virtually non-existent. This represents a significant unmet medical need.
Boomerang Medical seeks to fill this critical gap. The company champions bioelectronic medicine. This cutting-edge field merges biology and electronics. It develops innovative devices. These devices modulate specific nerve activity. Their approach involves sacral neuromodulation. A small, discreet implanted device delivers gentle electrical stimulation. This therapy modulates neural pathways. It aims to restore normal gut function. It works to alleviate symptoms. It strives to improve patient well-being significantly. Sacral neuromodulation boasts a robust safety profile. Over 500,000 procedures have occurred globally. These procedures successfully address other medical conditions. This extensive, proven track record underpins the therapy's safety. It provides a strong foundation for its application in IBD.
BOOM-IBD2 represents a groundbreaking effort. It is the first pivotal trial of implantable neuromodulation. The trial specifically targets IBD. Patient enrollment is actively underway. Leading medical centers across the United States participate. The clinical trial identifier is NCT06571669. This public registry ensures transparency. It highlights the rigorous scientific approach.
The trial design is not arbitrary. It draws from prior research. Boomerang Medical completed a 40-patient feasibility study. This study included both Crohn's disease and Ulcerative Colitis patients. The findings provided crucial insights. They informed BOOM-IBD2’s comprehensive design. Safety, tolerability, and early efficacy signals emerged. These early successes paved the way. They justify the larger pivotal investigation.
Boomerang Medical operates from a unique vantage point. It is headquartered in Mountain View, California. The company resides on the campus of El Camino Hospital. It holds a Company-In-Residence status. This affiliation is with Fogarty Innovation. Fogarty Innovation is a premier healthcare-focused incubator. It is the only one of its kind in the U.S. This environment fosters rapid medical device development. It cultivates groundbreaking solutions.
Leadership also defines Boomerang Medical. Heather Simonsen leads as CEO. The company is notably women-led. This highlights diversity in medical innovation. Their commitment to underserved populations is clear. Rigorous science guides their every step. Thoughtful innovation is their hallmark.
The potential impact is immense. Ulcerative Colitis is the most prevalent IBD form. Its widespread global impact demands urgent new solutions. Millions of lives hang in the balance. If successful, BOOM-IBD2 could introduce a completely new class of therapies. These pioneering device-based treatments would revolutionize care. They would target complex autoimmune gastrointestinal conditions. Such a breakthrough would redefine patient care. It would offer unprecedented new hope for millions of sufferers. This innovation signifies a paradigm shift in IBD management.
The Crohn’s & Colitis Foundation recognized Boomerang Medical. They named it an "Emerging Leader in IBD." This prestigious acknowledgment validates their work. It underscores their dedication to patient advocacy. It affirms their innovative trajectory.
Investors like Arboretum Ventures see clear value. Hatteras Venture Partners share this vision. They recognize the significant unmet need. They see the potential for a transformative solution. This $20 million investment positions Boomerang Medical strongly. It enables them to complete the pivotal trial. It moves this promising therapy closer to patients.
Boomerang Medical’s vision extends beyond Ulcerative Colitis. They aim to bring precision neuromodulation. It targets various underserved patient populations. This latest funding empowers this broader goal. It accelerates their clinical pipeline. The company stands ready to reshape the treatment landscape. This commitment drives progress in bioelectronic medicine. It promises a future with better outcomes for chronic conditions.